Corona Remedies Limited has commenced commercial production at its newly inaugurated EU-GMP approved Women's Hormone manufacturing facility located in Bhayla, Ahmedabad. The development strengthens the company's capabilities to serve domestic and international markets with specialised high-quality pharmaceutical products. The facility was inaugurated by Dr. K. L. Mehta, Chairman, alongside long-serving women employees of the organisation.

The new manufacturing unit is spread across 1.0 lakh sq. ft and is designed to handle complex hormonal medicines, which require stringent contamination control and specialised containment technologies. It supports multiple dosage forms — including tablets, soft gel capsules, ointments, and gels — within a single specialised ecosystem.

Capacity and Technology

With the commissioning of this facility, Corona Remedies Limited's in-house hormone manufacturing capacity is expected to increase by nearly 20%. The plant incorporates next-generation manufacturing technologies and digital process controls to ensure product consistency and operational excellence. The following table outlines the key capacity metrics of the new facility:

Key capabilities include fully integrated closed-loop manufacturing systems supported by 21 CFR-compliant equipment and Quality by Design (QbD) principles. The facility also features advanced gelatin processing systems with precision-controlled agitation and jacketed vessels for accurate temperature management.

Strategic Importance

Mr. Nirav K. Mehta, Founder, Managing Director & CEO, stated that the dedicated hormone facility represents the company's commitment to delivering globally benchmarked quality. He emphasised that scientific innovation must be complemented by world-class manufacturing capabilities to ensure women have access to safe and reliable hormone therapies.

The establishment of this facility addresses the growing need for specialised manufacturing driven by increasing demand for fertility care, menopause management, and hormone replacement therapies.

Sepia Investments Limited, along with persons acting in concert Anchor Partners and Sage Investment Trust, sold a combined 4,580,891 equity shares in Corona Remedies Limited on June 17, 2026. The transaction was executed through the open market on the National Stock Exchange of India Limited (NSE), reducing the sellers' collective stake in the pharmaceutical company.

The disclosures were made to the stock exchanges pursuant to Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The filing confirmed that the sellers do not belong to the promoter or promoter group of Corona Remedies Limited. The total equity share capital of the company remains INR 611,600,880, divided into 61,160,088 equity shares of face value INR 10 each.

Shareholding Details

The sale resulted in a reduction of holdings for all three entities. Sepia Investments Limited sold 4,328,943 shares, while Anchor Partners and Sage Investment Trust offloaded 161,861 and 90,087 shares, respectively.

Regulatory Filing

The disclosure, signed by Panir Pushpom Soobiah, Director of Sepia Investments Limited, and Ashley Menezes, Authorised Signatory for Anchor Partners and Sage Investment Trust, was submitted to BSE Limited and NSE on June 18, 2026. The document detailed the exact percentage changes relative to the total share capital and diluted share capital, which remained unchanged following the disposal.